AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued to investors on Tuesday, February 20th, MarketBeat Ratings reports. They presently have a $142.00 price target on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 22.23% from the company’s current price. Wedbush also issued estimates for AnaptysBio’s FY2022 earnings at $4.67 EPS.
ANAB has been the topic of a number of other reports. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 target price on the stock in a research report on Friday, November 10th. SunTrust Banks lifted their target price on AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Robert W. Baird reissued a “buy” rating and set a $144.00 target price (up from $81.00) on shares of AnaptysBio in a research report on Friday, January 19th. ValuEngine upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Jefferies Group raised their price target on shares of AnaptysBio from $6.59 to $145.00 and gave the stock a “buy” rating in a research note on Monday, February 19th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $129.67.
AnaptysBio (NASDAQ:ANAB) traded up $2.75 during midday trading on Tuesday, reaching $116.17. The company’s stock had a trading volume of 357,102 shares, compared to its average volume of 293,516. AnaptysBio has a one year low of $18.15 and a one year high of $134.00. The company has a current ratio of 17.93, a quick ratio of 17.93 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $2,697.66, a price-to-earnings ratio of -71.27 and a beta of 1.94.
Several large investors have recently bought and sold shares of ANAB. Wells Fargo & Company MN raised its position in AnaptysBio by 92.3% in the 3rd quarter. Wells Fargo & Company MN now owns 7,326 shares of the biotechnology company’s stock worth $256,000 after purchasing an additional 3,516 shares during the last quarter. JPMorgan Chase & Co. raised its position in AnaptysBio by 210.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after purchasing an additional 124,219 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in AnaptysBio by 69.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 32,846 shares of the biotechnology company’s stock worth $1,148,000 after purchasing an additional 13,444 shares during the last quarter. American International Group Inc. grew its holdings in AnaptysBio by 140.5% during the 3rd quarter. American International Group Inc. now owns 7,972 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 4,657 shares during the period. Finally, Brown Advisory Inc. acquired a new stake in AnaptysBio during the 4th quarter worth $6,549,000. Institutional investors own 99.25% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://stocknewstimes.com/2018/03/14/anaptysbio-anab-earns-outperform-rating-from-wedbush.html.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.